| Literature DB >> 32514464 |
Kodai Takahashi1, Yosuke Seki2, Kazunori Kasama2, Manabu Amiki2, Satoshi Baba3, Masayoshi Ito3, Tatsuro Tanaka3, Eiji Kanehira1.
Abstract
BACKGROUND: Currently, the data on the relationship between obesity and gastroesophageal reflux disease (GERD) in Asian populations are scarce.Entities:
Keywords: bariatric surgery; gastroesophageal reflux disease; obesity
Year: 2019 PMID: 32514464 PMCID: PMC7273729 DOI: 10.1002/jgh3.12293
Source DB: PubMed Journal: JGH Open ISSN: 2397-9070
Patients characteristics
| Variables |
|
|---|---|
| Gender, | |
| Male | 379 (56.3) |
| Female | 295 (43.7) |
| Age (years), mean ± SD | 41.2 ± 10.3 |
| BMI | 42.7 ± 9.24 |
|
| |
| Positive | 29 (4.3) |
| Negative | 645 (95.7) |
| Visceral/subcutaneous fat ratio, mean ± SD | 0.39 ± 0.19 |
| Visceral fat area (cm2), mean ± SD | 189.40 ± 141.50 |
| GERD‐related symptoms, | |
| Positive | 276 (41.0) |
| Negative | 398 (59.0) |
| LA classification, | |
| N | 316 (46.9) |
| M | 195 (28.9) |
| A | 114 (16.9) |
| B | 37 (5.5) |
| C | 11 (1.5) |
| D | 1 (0.2) |
| Barret esophagus, | |
| Positive | 11 (1.6) |
| Negative | 663 (98.4) |
| Hiatal hernia | |
| Positive | 268 (39.8) |
| Negative | 406 (60.2) |
| Medication (PPI), | |
| Positive | 60 (8.9) |
| Negative | 614 (91.1) |
BMI, body mass index; GERD, gastroesophageal reflux disease; LA, Los Angeles; PPI, proton pump inhibitor; RE, reflux esophagitis; SD, standard deviation.
The prevalence of RE in each group
| BMI (kg/m2) | 30< | 35< | 40< | 45< | 50< |
| Age (years), mean ± SD | 45.5 ± 9.3 | 41.1 ± 11.4 | 40.5 ± 10.4 | 40.2 ± 9.9 | 38.1 ± 8.3 |
| Number of patients | 27/130 | 43/179 | 35/139 | 27/101 | 31/125 |
| Ratio of patients (%) | 20.7 | 24 | 25.2 | 26.7 | 24.8 |
BMI, body mass index; RE, reflux esophagitis; SD, standard deviation.
The associations between RE and BMI
| LA classification | M, N | A, B, C, D | Univariate analysis ( |
|---|---|---|---|
| Number of patients | 163 | 511 | 0.24 |
| BMI (kg/m2) | 43.4 ± 9.3 | 42.5 ± 10.2 |
BMI, body mass index; RE, reflux esophagitis.
Figure 1The associations between the visceral fat area and body mass index (BMI) (Spearman's correlation coefficient). No significant correlation between the visceral fat area and BMI was noted (0.39 ± 0.19 and 42.7 ± 9.23, respectively; P < 0.0001).
The risk factors for RE in obese Japanese patients
| Variables | RE (+) | RE (−) | Univariate analysis ( |
|---|---|---|---|
| Gender, | <0.0001 | ||
| Male | 95 (14.1) | 200 (29.7) | |
| Female | 68 (10.1) | 311 (46.1) | |
| Age (years), mean ± SD | 41.8 ± 9.5 | 40.9 ± 10.5 | 0.22 |
|
| <0.02 | ||
| Positive | 2 (0.3) | 27 (4.0) | |
| Negative | 161 (23.9) | 484 (71.8) | |
| Visceral/subcutaneous fat ratio, mean ± SD | 0.4 ± 0.17 | 0.38 ± 0.19 | 0.11 |
| Visceral fat area (cm2), mean ± SD | 195.07 ± 74.35 | 187.59 ± 157.01 | 0.55 |
| GERD‐related symptoms, | <0.0001 | ||
| Positive | 88 (13.1) | 188 (27.9) | |
| Negative | 75 (11.1) | 323 (47.9) | |
| Barret esophagus, | 0.34 | ||
| Positive | 4 (0.6) | 7 (1.0) | |
| Negative | 159 (23.6) | 504 (74.8) | |
| Hiatal hernia, | <0.0001 | ||
| Positive | 104 (15.4) | 164 (24.3) | |
| Negative | 59 (8.8) | 347 (51.5) | |
| Medication (PPI), | 0.08 | ||
| Positive | 9 (1.3) | 51 (7.6) | |
| Negative | 154 (22.9) | 460 (68.2) |
GERD, gastroesophageal reflux disease; PPI, proton pump inhibitor; RE, reflux esophagitis; SD, standard deviation.
Multivariate logistic regression model associated with RE
| Univariate | Adjusted OR | 95% CI | Multivariate analysis ( |
|---|---|---|---|
| Male | 2.01 | 1.37–2.94 | 0.0003 |
|
| 4.87 | 1.36–31.2 | 0.01 |
| GERD‐related symptoms (positive) | 2.01 | 1.37–2.94 | 0.0003 |
| Hiatal hernia | 3.32 | 2.27–4.86 | <0.0001 |
CI, confidence interval; GERD, gastroesophageal reflux disease; OR, odds ratio; RE, reflux esophagitis.